| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 6826 from our risk checks.
Shanghai Haohai Biological Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$31.80 |
| 52 Week High | HK$35.86 |
| 52 Week Low | HK$21.71 |
| Beta | 0.77 |
| 11 Month Change | 4.63% |
| 3 Month Change | 12.71% |
| 1 Year Change | 36.77% |
| 33 Year Change | -61.45% |
| 5 Year Change | n/a |
| Change since IPO | -30.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6826 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 8.7% | -0.7% | -1.0% |
| 1Y | 36.8% | -34.6% | 0.7% |
Return vs Industry: 6826 exceeded the Hong Kong Biotechs industry which returned -34.6% over the past year.
Return vs Market: 6826 exceeded the Hong Kong Market which returned 0.7% over the past year.
Price Volatility
| 6826 volatility | |
|---|---|
| 6826 Average Weekly Movement | 4.4% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 6826 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6826's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,158 | Jianying Wu | www.3healthcare.com |
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop.
Shanghai Haohai Biological Technology Co., Ltd. Fundamentals Summary
| 6826 fundamental statistics | |
|---|---|
| Market cap | HK$14.15b |
| Earnings (TTM) | HK$464.79m |
| Revenue (TTM) | HK$2.89b |
16.1x
P/E Ratio2.6x
P/S RatioIs 6826 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6826 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.69b |
| Cost of Revenue | CN¥821.59m |
| Gross Profit | CN¥1.87b |
| Other Expenses | CN¥1.43b |
| Earnings | CN¥432.49m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 17, 2024
| Earnings per share (EPS) | 1.84 |
| Gross Margin | 69.44% |
| Net Profit Margin | 16.08% |
| Debt/Equity Ratio | 6.4% |
How did 6826 perform over the long term?
See historical performance and comparison